Treatment of minimal residual disease in myeloid malignancies after allo-HSCT with venetoclax-based regimens in patients ineligible for or failed in the immunotherapy
Background: Relapse was the major cause of treatment failure in patients with myeloid malignancies after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Patients who still suffer from the disease while cannot be detected by morphological analysis can be identified by the minimal resi...
Guardat en:
| Autors principals: | , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis Group
2024-12-01
|
| Col·lecció: | Hematology |
| Matèries: | |
| Accés en línia: | https://www.tandfonline.com/doi/10.1080/16078454.2024.2418653 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|